Despite taking a slight hit from the collapse in the health care sector in the past quarter, Sarepta Therapeutics Inc. (NASDAQ: SRPT) is still up significantly over the past year and was building momentum early on Thursday. The company announced additional clinical efficacy and safety data from the company’s Phase 2b program of eteplirsen in patients with Duchenne muscular dystrophy (DMD).
So far, the data demonstrated that eteplirsen provided a statistically significant advantage of 151 meters in the ability of study participants to walk at three years, compared with external controls. Additionally, the fourth biopsy data has confirmed the mechanism of action of eteplirsen, which demonstrated exon skipping in all patients and dystrophin production in nearly all patients. Safety data remained consistent with prior results.
Eteplirsen is designed to target the underlying cause of DMD by enabling the production of a functional dystrophin protein in patients with mutations amenable to exon 51 skipping. Roughly 13% of people with DMD are estimated to have a mutation targeted by eteplirsen/exon 51 skipping.
Edward Kaye, M.D., Sarepta’s interim CEO and chief medical officer, said:
We are encouraged by the positive clinical outcomes, such as the statistically significant difference in the 6MWT in eteplirsen-treated patients compared to a control, especially since we see them accompanied by data that continues to demonstrate exon skipping and dystrophin production in most patients. We are committed to bringing eteplirsen and our other investigational exon skipping therapies to patients with DMD and will continue to work with all stakeholders to advance these programs as quickly as possible so we can better address the unmet need for treatments in the DMD community.
Shares of Sarepta closed Wednesday up 0.7%, at $32.11 in a 52-week trading range of $11.33 to $41.47. In early trading indications on Thursday, shares were up 18% at $37.90. The stock has a consensus analyst price target of $41.75.
ALSO READ: 2 Deutsche Bank Health Care Focus Stocks With Big Upside Potential
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
